(032) Prevalence of Testosterone Deficiency and Risk Factors in Patients with Localized Prostate Cancer After Radical Prostatectomy

Abstract

Abstract Introduction Testosterone therapy (TTh) is contra-indicated in patients with prostate cancer (PCa), however according to the recent AUA guideline, TTh can be offer for localized PCa with no evidence of active disease. However, it is not known how much localized PCa patients suffer from testosterone (T) deficiency after treatment in real clinical practice, and further clinical characteristics on those potential candidates for TTh is insufficient. Objective This study analyzed T profile of patients with localized PCa who underwent radical prostatectomy (RP) to determined the prevalence of testosterone deficiency and its risk factors. Methods We reviewed patients who underwent RP for localized PCa between 2016 and 2021. Patients with less than 1 year of follow-up and patients with biochemical recurrence or distant metastasis during follow-up were excluded. In addition, we exclude the patient who had no T profile preoperatively and postoperative 1 year. The serum T level threshold for T deficiency was defined as 3.0 ng/mL. The primary outcome was the prevalence of TDS, and the secondary outcome was the predicting factors of TDS. Results A total of 192 patients underwent RP with localized PCa during the study period. Among them, 120 patients were analyzed, excluding patients without baseline T and follow-up T level at postoperative 1 year (n=67) and patients with BCR during the follow-up (n=5). Eighteen of 120 patients (15.0%) had T deficiency before RP. Excluding preoperative T deficiency, 33 (32.4%) of 102 patients had their T level reduced to less than 3.0 ng/ml after RP. Among them, 16 patients (15.7%) had persistent decreased T level. Table 1. Summarized the baseline characteristics of patients with and without T deficiency after RP. BMI (OR: 1.586, p< 0.001) was statistically significant in multivariate logistic regression to identify the predicting factor for T deficiency after RP. Conclusions In the patients with localized prostate cancer, there were a significant number of TTh candidates. In particular, obese patients had a higher risk of T deficiency. Disclosure No.